Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 19:00:35 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Faron Pharmaceuticals H1 2023 - Clinical advancements

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Faron Pharmaceuticals H1 2023 - Clinical advancements

2023-08-30 08:10:00

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our estimates for OPEX following a slightly lower cash burn than expected. However, we reiterate our base case valuation as we continue to see a compelling case rooted in an exciting clinical pipeline.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/